Startup profile for Kin Health: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

Kin Health funding, valuation and investors

Free patient-facing AI app that records visits and turns doctor conversations into actionable summaries.

Keep track of Kin Health

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Seed

$9M · May 2026

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$9M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

seed · Los Angeles, CA

Investors in latest funding

Lead: Maveron

Other: Eniac Ventures , Pear VC

Sources: latest funding Last verified: 2026-07-25

Overview

Kin Health offers a free mobile app that records medical appointments and produces plain-language summaries patients can act on and share with caregivers. Founded by physicians Arpan and Amit Parikh with Kyle Alwyn (HeyDoctor, acquired by GoodRx) and GoodRx co-founders Doug Hirsch and Trevor Bezdek as investors/chairmen, Kin raised $9M seed in May 2026 led by Maveron with Eniac Ventures, Pear VC, Town Hall Ventures, and others participating.

Why Kin Health is interesting

Clinician scribes are crowded — Kin targets the patient side of the conversation and monetizes downstream care navigation like GoodRx did.

Product & use cases

Consumer health app: ambient recording of visits, plain-language summaries, personal health record built from conversations, planned care navigation referrals.

  • Patients remembering specialist instructions after visits
  • Caregivers sharing visit summaries with family
  • Downstream lab, pharmacy, and specialist routing (planned revenue)

Key facts

  • Seed (May 2026): $9M led by Maveron
  • GoodRx founders Hirsch and Bezdek involved
  • Free consumer app; downstream monetization model
  • 30+ physician angels in round

Funding history (newest first)

Investors in our directory

Funds linked from Kin Health's profile — open a fund page for stage focus and related deal articles.

Competitive landscape

Edge: Permanently free consumer app with GoodRx-style downstream monetization versus subscription patient tools.

Patient ambient AI must avoid hallucinations in medical contexts — Kin emphasizes clinical rigor engine. Free UX drives adoption; revenue depends on ethical downstream routing economics.

  • Heidi / Freed (clinician scribes) adjacent

    Provider-side notetakers; Kin is patient-facing.

  • Patient portal visit summaries incumbent

    EHR portals with clinician notes, often jargon-heavy.

  • General health record apps adjacent

    Apple Health records without conversation capture.

Notable stories

  • TechCrunch noted Kin flips the scribe market — $600M+ clinician notetaker revenue vs underserved patients.
  • Alwyn sold HeyDoctor to GoodRx in 2019 before founding Kin's technical stack.

Industries

Healthtech AI & Machine Learning Consumer

Related funding articles

Venture Capital Tracker pieces that cover Kin Health's financing or category context.

FAQs about Kin Health

Practical answers founders, operators, and investors typically search for.

Free app recording doctor visits and summarizing them in plain language for patients.
Maveron led; Eniac Ventures and Pear VC participated. See /fund/eniac-ventures and /fund/pear-vc.
$9M seed in May 2026.
Yes — permanently free for consumers per company announcements.
Planned downstream care navigation (labs, specialists, prescriptions) similar to GoodRx economics.
Kin is patient-facing; Freed/Heidi target clinicians.
Physicians Arpan and Amit Parikh with Kyle Alwyn.
Los Angeles / Westwood per LA Business Journal.
Healthcare app handling PHI; company emphasizes security and clinical rigor.
Technical founder; previously co-founded HeyDoctor (sold to GoodRx).

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.